Tags Posts tagged with "pharma"

pharma

Amazon continues to stay mum on its healthcare ambitions but if you put the pieces together, it’s clear there’s some sort of play in the works. This past year, rumors swirled around the clandestine 1492 lab, focused, among other things, on electronic...

As recently noted in a Wall Street Journal article, some private equity (PE) firms have begun partnering with pharmaceutical companies, though in a manner far from traditional. Instead of buying nascent fledgling biotech firms outright, these PE companies have begun providing...

In contrast to M&A levels in many other sectors, deal making activity in the pharmaceutical and biotechnology industries remained strong in 2016, but is this area likely to stay hot in 2017? In the latest edition of our quarterly report series, Firmex...

When Horizon Pharma PLC bought Crealta Holdings LLC for US$510 million in January, it took only six weeks to merge Crealta's financial information into the biopharmaceutical company's back-end software.  In the past, that same integration could have taken a year or...

Despite a slight dip in Q3, it continues to be a strong year for worldwide M&A activity. Here's some highlights from Thomson Reuters latest Trends in Deal Making webinar.
Trends In Deal Making – Webinar Recap

In H1 2014, worldwide M&A activity was up 73% compared to the same period in 2013, and cross-border M&A doubled. Here's some highlights from Thomson Reuter's latest Trends in Deal Making webinar.

Tempting overseas tax rates are encouraging many U.S. companies to pursue cross-border deals. A number of deal inversions have been explored or attempted in the last two years alone.

Monoclonal antibodies (mAbs) represent one of the most successful therapeutic drug classes, attracting billions of investment dollars for the biotechnology industry. Last week AstraZeneca’s global biologics research and development arm, MedImmune, became the latest mAb player. MedImmune acquired Spirogen, a privately held...

2012 was a healthy year for the U.S. pharmaceuticals industry, with 39 new drugs approved - the highest in 16 years. This trend was largely driven by a string of recent patent expirations, with generic drug makers able to offer cheaper alternatives...

Today we enjoyed an in-depth outlook of the M&A Market in 2012  with Dennis Roberts, author, Chairman and CEO at The McLean Group. His insights into how cross-border deals, technology, healthcare and an aging baby boomer population are affecting the M&A...